尼莫地平对原发性开角型青光眼的疗效观察

An observation on the effects of nimodipine in the treatment of primary open-angle glaucoma

目的观察尼莫地平对原发性开角型青光眼的治疗效果。方法原发性开角型青光眼患者22例(36眼),分为两组,两组患者的眼压均控制在18mmHg以下,其中一组予口服尼莫地平,治疗前后分别检测视力、眼压和视野(用视网膜平均光敏感度代表),采用t检验和掊2检验比较两组之间的差异。结果治疗6、12个月时,尼莫地平组的视网膜平均光敏感度分别为(16.48±3.05)dB和(16.05±2.47)dB,对照组分别为(12.36±2.64)dB和(10.49±2.58)dB,两组比较有显著性差异(t=4.43,6.54,P﹤0.01)。治疗12个月时,尼莫地平组有2眼出现视野进行性损害,对照组有7眼出现视野进行性损害,两组比较有显著性差异(X2=5.40,P﹤0.05)。治疗前后各时间段两组的眼压和视力无显著性差异。应用尼莫地平的患者未出现明显的药物不良反应。结论尼莫地平可能有利于保护或改善青光眼患者的视野。

Objective To study the effects of nimodipine in the treatment of primary open-angle glaucoma （POAG）. Methods 22 patients （36 eyes） with POAG were divided into two groups. All patients had intraocular pressure （lOP） controlled under 18mmHg. Patients in nimodipine group were given nimodipine orally and patients in the other group did not.Visual acuity, IOP and visual field（represented by mean sensitivity, MS） were measured at baseline and after treatment. The data were processed for statistical analysis with Student＇s t-test and Chi-square test for the differences between these two groups before and after treatment. Results ＇After 6, 12 months of treatment, the MS in nimodipine group were （16.48±3.05）dB and （16.05±2.47）dB,respectively, whereas the MS in the other group were （12.36±2.64）dB and （10.49±2.58）dB respectively. There was signigicant difference in MS between these two groups （t=4.43, 6.54, P 〈 0.01）; progressive loss of visual field occurred in two eyes in nimodipine group and seven eyes in the other group, which had signigicant difference between these two groups （X^2=5.40, P 〈 0.05）. There was no significant differences in IOP and visual acuity at each time point before and after treatment. No serious side effects appeared in patients with nimodipine. Conclusions Nimodipine may preserve and improve the visual field of patients with POAG.